Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference

Lipocine Inc.
Posted on: 14 Mar 18
Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference

PR Newswire

SALT LAKE CITY, March 14, 2018

SALT LAKE CITY, March 14, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20th – 21st at the Westin Grand Central Hotel in New York City.

Presentation Details

Date:                          

Wednesday, March 21st   

Time:                          

3:55pm Eastern Time

Location:                    

Westin Grand Central Hotel, Consulate Ballroom

Webcast:                    

https://veracast.com/webcasts/opco/healthcare2018/93216258627.cfm

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-300613266.html

SOURCE Lipocine Inc.

PR Newswire
www.prnewswire.com

Last updated on: 14/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.